• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

byMinjee Kim
October 26, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months)

2. The enzalutamide group had more fatigue and asthenia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Metastatic castration-resistant prostate cancer (mCRPC) has been treated with effective first-line therapies docetaxel (chemotherapy) with neo/adjuvant enzalutamide (androgen receptor inhibitor) based on past trials including AFFIRM and PREVAIL. Yet what remains unclear is the choice of therapy should there be disease progression with the above treatment plan. This randomized phase 3b trial investigates treatment for patient with mCRPC who had disease progression after therapy with enzalutamide. Patients were randomized into either receiving enzalutamide or placebo, in addition to a standard dose of docetaxel and prednisolone. The primary endpoint was progression-free survival and the secondary endpoints included time to PSA progression, PSA response, objective response rate, and more. It was found that the median progression-free survival was 9.5 months in the enzalutamide vs 8.3 months in the placebo group. Median time to PSA progression was 8.4 months in the enzalutamide group vs 6.2 months in the placebo group. Objective response rates were similar in both groups (41% vs 39% respectively). Grade 3 or higher adverse events also occurred at similar rates for both groups and the most common adverse events included neutropenia, asthenia, alopecia, fatigue, diarrhea, and anemia. Limitations to this study was that it was not powered for overall survival, selected a low risk-population as the eligible patients had higher functional status and had endocrine-responsive cancers. Strengths of this study included its large sample size, and its randomization. Overall, in patients with mCRPC who have disease progression despite enzalutamide therapy, continuing enzalutamide with docetaxel has shown to be effective.

Click to read the study in Lancet Oncology

RELATED REPORTS

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Exercise improves sexual function in men with prostate cancer  

Genome classifiers may aid prostate cancer risk stratification and treatment

Relevant Reading: Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

In-Depth [randomized controlled trial]: PERSIDE was a multinational double blinded randomized placebo-controlled phase 3b trial which enrolled patients with histologically confirmed prostate adenocarcinoma who progressed with androgen deprivation therapy. Patients were first enrolled in period 1 and received enzalutamide 160mg daily until disease progression, defined as elevations in PSA and radiographic assessment. Those who had disease progression were randomized in period 2 into either receiving enzalutamide 160mg daily or placebo, in addition to a standard dose of docetaxel and prednisolone. 688 patients were enrolled in period 1, and 271 patients had disease progression and were randomly assigned in period 2. The median follow-up time was 8.1 months in the enzalutamide group (136 patients) and 6.3 months in the placebo group (135 patients). Median progression-free survival was 9.5 months (95%CI, 8.3-10.9) in the enzalutamide group and 8.3 months (95%CI, 6.3-8.7) in the placebo group, which resulted in HR 0.72 (95%CI, 0.53-0.96, p=0.027). Disease progression occurred in 74% of the enzalutamide group vs 76% in the placebo group. Median time to PSA progression was 8.4 months (CI95%, 8.2-9.0) in the enzalutamide group vs 6.2 months (CI95%,5.4-8.3) in the placebo group, HR 0.58 (95%CI, 0.41-0.82). The objective response rates were 41% (8CR/13PR) in the enzalutamide group vs 39% (7CR/16PR) in the control group. Grade 3/grade 4 adverse events occurred in 38%/24% vs 37%/25% in the enzalutamide compared to placebo, respectively. The most common adverse events included neutropenia (highest amount of grade 3/4 events), asthenia, alopecia, fatigue, diarrhea, and anemia. Overall, continuing treatment with enzalutamide/docetaxel was shown to be effective when compared to placebo/docetaxel in patients with mCRPC.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #mCRPCAFFIRM trialdocetaxelenzalutamidemetastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)metastatic prostate cancerPRESIDE trialPREVAIL trialprostate adenocarcinomaprostate cancerPSAPSA progression
Previous Post

Chlorhexidine and povidone-iodine equally effective for skin antisepsis of open fractures undergoing surgical fixation

Next Post

Financial incentives effective in increasing smoking cessation rates in the UK

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Androgen deprivation in prostate cancer: intermittent may compromise survival
Chronic Disease

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

December 18, 2024
Next Post
Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Financial incentives effective in increasing smoking cessation rates in the UK

Wound surgical device found ineffective at infection control: ROSSINI Trial

Oxygenation strategies inconsequential in comatose survivors of cardiac arrest

#VisualAbstract: Ivermectin does not improve recovery time in adults with mild to moderate COVID-19 infection

#VisualAbstract: Ivermectin does not improve recovery time in adults with mild to moderate COVID-19 infection

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.